1887

Abstract

Summary

The effect of rabbit anti-rubella virus (RV) serum on the course of RV infection of human lymphoid cells has been examined. The antibody was found to abolish viral replication such that no virus progeny could be detected either extracellularly (after removal of the antiserum) or intracellularly, in the treated cells. Viral protein synthesis was also found to be totally inhibited in the presence of anti-RV but resumed immediately on removal of the antibody block at levels suggesting that viral RNA had been accumulating in the cell. Infectious focus assays indicated that the effect could be explained in part by the restriction by antiviral antibody of cell-to-cell spread in the indicator monolayer. Thus by 48 h when 100% of lymphoid cells infected with virus alone were capable of forming infectious foci, only 40 to 50% of cells infected in the presence of antiviral antibody produced foci. However this restriction imposed by antibody did not adequately explain the total inhibition of viral protein synthesis that occurred under these conditions. Pretreatment of RV with excess neutralizing antiserum reduced the virus titre > 99.9% but did not eliminate infectious virus. The ‘non-neutralized’ fraction (10 to 10 p.f.u./ml) brought about a productive infection with final yields of 10 to 25% of control titres (> 10 p.f.u./ml). Incubation of virus with both anti-RV and goat anti-rabbit Ig eliminated viral infectivity, indicating that the ‘non-neutralized’ fraction was in the form of infectious immune complexes. The results suggest two major modes of action for anti-RV antibody, one in neutralizing extracellular virus, the second exerted on the infected cells, totally inhibiting viral translation and thus preventing the virus from completing its replicative cycle.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-68-5-1277
1987-05-01
2019-10-23
Loading full text...

Full text loading...

http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-68-5-1277
Loading

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error